Researchers at UCSF have discovered an unexpectedly high rate of COVID rebound following treatment with Paxlovid.
A group of scientists from the University of California, San Francisco, discovered that Paxlovid (Nirmatrelvir-ritonavir) was ineffective in lowering the chances of vaccinated, non-hospitalized patients contracting long COVID during their initial infection with the virus. Additionally, they observed a greater frequency of acute symptom recurrence and test positivity for the virus than what had been earlier documented.

The study was recently published in the Journal of Medical Virology.

Paxlovid treatment for acute COVID-19 has been shown to be effective for high-risk unvaccinated individuals. But the effect of the treatment on long COVID risk, including whether it protects vaccinated people from getting long COVID, has been less clear.

[ Ссылка ]

свернуть